Sorrento Therapeutics Inc. (SRNE): Wildcat Capital Management Files a Complaint

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 13D
(Rule 13d-101)

(Amendment No. 4)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a)

If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note.
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7
for other parties to whom copies are to be sent.

(Continued on following pages)

(Page 1 of 13 Pages)

______________________

* The remainder of this cover page shall be filled
out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this
cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

This Amendment No. 4 (the “Amendment”)
amends and supplements the Schedule 13D filed on April 18, 2016, as amended and supplemented by Amendment No. 1 filed on April
26, 2016, Amendment No. 2 filed on May 6, 2016 and Amendment No. 3 filed on May 11, 2016 (as so amended, the “Original
Schedule 13D” and, as further amended and supplemented by this Amendment, the “Schedule 13D”) by Wildcat
Capital Management, LLC, Wildcat – Liquid Alpha, LLC, Infinity Q Capital Management, LLC, Infinity Q Management Equity, LLC,
Infinity Q Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard A. Potter and James Velissaris with respect to
the Common Stock of the Issuer. Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings
ascribed to them in the Original Schedule 13D.

Item 4.  Purpose of Transaction

This Amendment amends and supplements Item 4
of the Original Schedule 13D by inserting the following after the sixth paragraph:

“On May 13, 2016, WLA, on behalf of the
Issuer, filed a verified derivative complaint (the “May 13 Complaint”) asserting derivative claims for breach of fiduciary
duty, waste of corporate assets, and unjust enrichment against Dr. Ji and directors William S. Marth, Kim D. Janda, Douglas Ebersole,
Jaisim Shah and David H. Deming (collectively, the “Defendants”).  Pursuant to the May 13 Complaint, WLA,
on behalf of the Issuer, seeks to, among other things: (i) enjoin the three private placements that are part of the Transactions
that have not already closed but are expected to close imminently; (ii) rescind the options and warrants issued by the Issuer’s
subsidiaries to Dr. Ji and the Board; and (iii) be awarded damages resulting from the Defendants’ alleged breaches of fiduciary
duties and other alleged misconduct.  A copy of the May 13 Complaint is attached as Exhibit 6.  Also on May 13, 2016,
WLA filed a motion for a temporary restraining order (the “May 13 Motion for TRO”) against the Defendants seeking
that the court enter a temporary restraining order pending a preliminary injunction hearing (i) enjoining the Defendants and the
Issuer from taking any further steps to consummate the Transactions or any associated voting agreements; and (ii) enjoining Defendants
and the Issuer from instructing Yuhan Corporation (“Yuhan”), to vote its shares in connection with the voting
agreement associated with Yuhan’s investment as part of the Transactions.  Copies of each of the May 13 Motion for TRO
and brief in support of the May 13 Motion for TRO are attached as Exhibits 7 and 8, respectively.”

Item 7. Material to Be Filed as Exhibits

This
Amendment amends and restates Item 7 of the Original Schedule 13D in its entirety as set forth below:

SIGNATURE

After reasonable inquiry and to the best
of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: May 16, 2016

INDEX TO EXHIBITS

_________________

⁽¹⁾ Incorporated
herein by reference to the Agreement of Joint Filing by and among Wildcat Capital Management, LLC (“Wildcat”),
Wildcat – Liquid Alpha, LLC (“WLA”), Infinity Q Capital Management, LLC (“IQCM”), Infinity
Q Management Equity, LLC (“IQME”), Infinity Q Diversified Alpha Fund (“IQDA”), Bonderman
Family Limited Partnership (“BFLP”), Leonard A. Potter and James Velissaris, dated as of April 18, 2016, which
was previously filed with the SEC as Exhibit 1 to Schedule 13G filed by Wildcat Capital Management, LLC, Wildcat – Liquid
Alpha, LLC, Infinity Q Capital Management, LLC, Infinity Q Management Equity, LLC, Infinity Q Diversified Alpha Fund, Bonderman
Family Limited Partnership, Leonard A. Potter and James Velissaris, on April 18, 2016.

⁽²⁾ Incorporated
herein by reference to Demand for Inspection of Books and Records, dated April 11, 2016, which was previously filed with the SEC
as Exhibit 2 to Schedule 13D filed by Wildcat, WLA, IQCM, IQME, IQDA, BFLP, Leonard A. Potter and James Velissaris, on April 18,
2016.

⁽³⁾ Incorporated
herein by reference to Verified Complaint for Inspection of Books and Records filed in the Court of Chancery of the State of Delaware
on April 25, 2016, which was previously filed with the SEC as Exhibit 3 to Amendment No. 1 to Schedule 13D filed by Wildcat, WLA,
IQCM, IQME, IQDA, BFLP, Leonard A. Potter and James Velissaris, on April 26, 2016.

⁽⁴⁾ Incorporated
herein by reference to Letter to the Board of Directors of the Issuer, dated May 5, 2016, which was previously filed with the SEC
as Exhibit 4 to Amendment No. 2 to Schedule 13D filed by Wildcat, WLA, IQCM, IQME, IQDA, BFLP, Leonard A. Potter and James Velissaris,
on May 6, 2016.

⁽⁵⁾ Incorporated
herein by reference to Letter to the Board of Directors of the Issuer, dated May 10, 2016, which was previously filed with the
SEC as Exhibit 5 to Amendment No. 3 to Schedule 13D filed by Wildcat, WLA, IQCM, IQME, IQDA, BFLP, Leonard A. Potter and James
Velissaris, on May 11, 2016.